2023年2月2日,

——第一阶段研究将评估的安全性和耐受性olx保持07010年的健康志愿者,02年2月,2023年塔利班东部标准时间上午白色平原,纽约——(业务线)——Oligomerix, Inc .私人控股公司开创性的发展小分子疗法针对τ罕见的神经退行性和阿尔茨海默疾病今天宣布首次剂量的受试者在公司的第一阶段临床试验评估领先候选人olx保持07010。这个铅化合物是一种新型口服,小分子抑制剂的τself-association评估治疗老年痴呆症和其他神经退行性疾病。第一阶段研究的目的是评估的安全性和耐受性olx保持07010年single-ascending multiple-ascending剂量方案在健康的志愿者,紧随其后的是评估在一群健康的老年志愿者,预期的人口。“有针对性的安全性和有效性的影响力,olx保持07010有可能填补一个重要空白对病人的治疗方案毁灭性的神经退行性疾病,”詹姆斯·莫尔说,博士,首席执行官MBA和Oligomerix发现和战略主管。“我为整个Oligomerix团队感到骄傲和兴奋是重要里程碑的一部分在我们开始first-in-human临床试验。”在非临床药效学研究,07010年olx保持了强劲的功效在两种不同小鼠模型的神经退化。数据从07010年olx保持非临床研究已经在世界级的神经病学会议和发表在同行评议的期刊。在临床前,IND-enabling研究,olx保持07010被证明是一个优秀的候选人进行临床研究。“这是至关重要的神经科学社区继续努力开发出更好的治疗策略严重的神经系统疾病,”威廉·Erhardt说,医学博士总裁兼Oligomerix开发与运营主管。 “Over the last two years, Oligomerix has made significant progress in demonstrating how inhibiting tau self-association can have remarkable effects in preclinical models of AD and neurodegenerative conditions. With the start of this Phase 1a study, we look forward to working closely with our stakeholders, from patients to caregivers to regulatory officials, as we characterize the clinical profile of OLX-07010.” Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number 1R01AG076565-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About OLX-07010 OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders. Oligomerix’s lead candidate has demonstrated efficacy in multiple animal models of tau-mediated neurodegeneration. OLX-07010 is currently being evaluated in a Phase 1a clinical trial in healthy subjects. For more information, please visit clinicaltrials.gov . About Oligomerix, Inc. Oligomerix is a clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are potentially easy to administer and cost-effective. Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative or complement the newly emerging high-cost therapeutic options such as monoclonal antibody products. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on LinkedIn . Oligomerix is seeking strategic partnerships to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our website at https://oligomerix.com/ . Contacts